Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post–Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients  by Koren-Michowitz, Maya et al.
M. Koren-Michowitz et al. / Biol Blood Marrow Transplant 21 (2015) 1839e1855185246. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, puriﬁca-
tion, and functional assessment of human peripheral blood NK cells.
J Visual Exp. 2011;48:1-5.
47. Ortaldo JR, Mason A, Willette-Brown J, et al. Modulation of lymphocyte
function with inhibitory CD2: loss of NK and NKT cells. Cell Immunol.
2007;249:8-19.
48. Foley B, Felices M, Cichocki F, et al. The biology of NK cells and their
receptors affects clinical outcomes after hematopoietic cell trans-
plantation (HCT). Immunol Rev. 2014;258:45-63.
49. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis
and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017.
50. Badell IR, Russell MC, Thompson PW, et al. LFA-1-speciﬁc therapy
prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120:
4520-4531.
51. Reisman NM, Floyd TL, Wagener ME, et al. LFA-1 blockade induces
effector and regulatory T-cell enrichment in lymph nodes and syner-
gizes with CTLA-4Ig to inhibit effector function. Blood. 2011;118:
5851-5861.Financial disclosure: See Acknowledgments on page 1854.
* Correspondence and reprint requests: Maya Koren-Michowitz, Division
of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-
Gan 52621, Israel.
E-mail address:m.koren.michowitz@gmail.com (M. Koren-Michowitz).
http://dx.doi.org/10.1016/j.bbmt.2015.06.018
1083-8791/ 2015 American Society for Blood andMarrow Transplantation.52. Adkins D, Ratanatharathorn V, Yang H, White B. Safety proﬁle and
clinical outcomes in a phase I, placebo-controlled study of siplizumab
in acute graft-versus-host disease. Transplantation. 2009;88:198-202.
53. Pruett TL, McGory RW, Wright FH, et al. Safety proﬁle, pharmacoki-
netics, and pharmacodynamics of siplizumab, a humanized anti-CD2
monoclonal antibody, in renal allograft recipients. Transplant Proc.
2009;41:3655-3661.
54. Langley RG, Papp K, Bissonnette R, et al. Safety proﬁle of intravenous and
subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the
treatment of plaque psoriasis: results of two randomized, double-blind,
placebo-controlled studies. Int J Dermatol. 2010;49:818-828.
55. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated
progressive multifocal leucoencephalopathy in patients treated with
rituximab, natalizumab, and efalizumab: a review from the Research
on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol.
2009;10:816-824.
56. Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic
therapy in systemic lupus erythematosus. BMC Med. 2014;12:30.Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL
Shows Deep Molecular Responses in Long-Term
PosteAllogeneic Stem Cell Transplantation Chronic Myeloid
Leukemia PatientsMaya Koren-Michowitz 1,2,*, Avichai Shimoni 1, Filomena Daraio 3,
Francesca Crasto 3, Roberta Lorenzatti 3, Yulia Volchek 1, Ninette Amariglio 1,
Enrico Gottardi 3, Giuseppe Saglio 3, Arnon Nagler 1,2
1Division of Hematology, Chaim Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga University Hospital, Turin,
ItalyArticle history:
Received 2 April 2015
Accepted 20 June 2015
Key Words:
Quantitative PCR
Stem cell transplantation
Chronic myeloid leukemiaa b s t r a c t
Real-time quantitative PCR (RT-qPCR) is commonly used for follow-up of chronic myeloid leukemia (CML)
patients treated with tyrosine kinase inhibitors, but its current sensitivity does not allow detection of very
low BCR-ABL levels. Therefore RT-qPCR negativity is not synonymous with complete molecular response.
Replicate RT-qPCR had shown increased sensitivity in tyrosine kinase inhibitoretreated patients and was,
therefore, used here to evaluate whether RT-qPCRenegative posteallogeneic stem cell transplantation (SCT)
patients harbor detectable disease. Samples from 12 patients were tested at 2 time points using 82 replicates
of BCR-ABL RT-qPCR. One patient (38 months after SCT) had detectable transcripts at baseline and none at the
follow-up test, done at a median of 107 months after SCT. This suggests cure from CML in the majority of
allogeneic SCT patients who have no transcripts detectable by replicate RT-qPCR for BCR-ABL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Treatment with ABL tyrosine kinase inhibitors (TKI) has
become the cornerstone of chronic myeloid leukemia (CML)
therapy in recent years. Chronic phase CML patients
achieving deep molecular responses (MR) on long-term TKI
therapy may be thought of as having a “functional” cure and
withholding TKI treatment in patients with continuous deep
responses is currently under intensive investigation [1,2].Nevertheless, allogeneic (Allo) stem cell transplantation
(SCT) is still the only modality with proven efﬁcacy in
advanced phase cases and is a valid option in TKI-resistant
cases. Absence of BCR-ABL transcripts after SCT with sensi-
tive methods (ie, achieving PCR negativity) correlates with
long-term disease-free survival, whereas re-emergence of
BCR-ABL transcripts has been shown to predict disease
relapse and is, therefore, used to trigger therapeutic in-
terventions, such as the addition of a TKI or donor lympho-
cyte infusion [3-6]. With the widespread use of PCR to detect
BCR-ABL transcripts, it has become clear that achieving PCR
negativity is not synonymous with molecular complete
response but rather depends on the sensitivity of themethod
used and technical variables, such as the RNA quality in each
speciﬁc sample [7]. Real-time quantitative PCR (RT-qPCR) is
the most commonly used method for follow-up of CML
Table 1
Characteristics of Study Patients
Patient
No.
Age,
yr
Disease
Status
at SCT
Time from
Diagnosis
to SCT, mo
Conditioning Donor Chronic
GVHD
1 57 AP 97 RIC MUD þ
2 30 CP2 6 MA Sibling þ
3 48 CP2 273 MA MUD þ
4 52 CP1 4 RIC Sibling þ
5 34 CP1 16 MA MUD þ
6 30 CP1 39 MA Sibling 
7 40 CP1 6 MA Sibling þ
8 68 CP1 61 RIC MUD þ
9 46 CP1 33 RIC MUD þ
10 56 CP1 18 RIC Sibling þ
11 38 AP 6 RIC Sibling þ
12 23 CP2 3 MA Sibling þ
GVHD indicates graft-versus-host disease; AP, accelerated phase; RIC,
reduced-intensity conditioning; MUD, matched unrelated donor; CP,
chronic phase; MA, myeloablative.
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on when and how to perform it, as well as how to interna-
tionally standardize the PCR results [8]. With a sensitivity of
approximately 104 for the commonly used RT-qPCR, pro-
gressive reductions in BCR-ABL transcript levels correlate
well with long-term outcomes with TKI therapy but may not
be sensitive enough to detect low-level transcript changes
after Allo-SCT. Replicate RT-qPCR (rRT-qPCR) utilizes regular
RT-qPCRmethods but has the advantage of repeating the test
using many more replicates. Studies have conﬁrmed that
the number of measurement repetitions is relevant in the
detection of rare transcripts, and rRT-qPCR was found to be
more sensitive than conventional RT-qPCR [9]. We, therefore,
utilized this method to study whether BCR-ABL transcriptsFigure 1. Individual patient RT-qPCR and rRT-qPCR results after Allo-SCT. Levels of m
qPCR (in blue) and rRT-qPCR (in red). MMR indicates major molecular response. (Thican still be detected in RT-qPCRenegative post-SCT CML
patients after long-term follow-up.SUBJECTS AND METHODS
Consecutive post-SCT CML patients undergoing follow-up in the SCT day
care unit of the Sheba Medical Center in Israel were recruited to the study.
Patients had to have at least 2 sequential RT-qPCR negative results before
inclusion in the study, although they were not excluded from analysis if a
concurrent RT-qPCR done at the same date of rRT-qPCR reported positive
results. The study was approved by the local institutional review board, and
all patients gave their informed consent. Peripheral blood was collected into
EDTA-containing tubes at 2 separate time points. Buffy coats were imme-
diately prepared and white blood cell pellets homogenized in the Trizol
reagents were frozen at 80C until further analysis.rRT-qPCR
rRT-qPCR was done in the hematological molecular laboratory in
Orbassano, Italy, as previously described [10-12]. Brieﬂy, RNA was reverse
transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche,
Mannheim, Germany). cDNA synthesis was achieved by incubating at 25C
for 10 minutes and at 42C for 60 minutes, and then the reaction was
inactivated by heating at 99C for 5 minutes. The qPCR reactionmix for each
well included 2 uL of cDNA, 300 nM of each primer (BCR-ABL F-gatgctgac-
caactcgtgtg; BCR-ABL R-aacgaaaaggttggggtcat; ABL F- gaagccgctcgttggaact;
ABL R-cctaagacccggagcttttca), and 200 nM probe (BCR-ABL agaccctgaggct-
caaagtcagatgctact; ABL-agagtgttatctccactggccacaaaatca). The assay was
carried out in 82 wells for each patient’s sample in custom-made plates
(Applied Biosystems, Foster City, CA) using a LightCycler 480 analyzer
(Roche) under the following conditions: 95C for 10 minutes, 50 cycles
including 95C for 10 seconds, 60C for 1minutes for 50 cycles, and a cooling
step at 45C for 5 minutes.
All samples from each time point were studied at the same time. Results
were reported as the mean percentage of BCR-ABL relative to ABL transcripts
and normalized according to the international scale [8,13]. Blood from 14
healthy controls was used to determine the test background, determining
the cutoff of 2.7 (mean þ 2 SD) positive wells. Results were considered
positive when above the background [14]. PCR sensitivity in each reaction
was determined by calculating the total number of ABL transcripts detected
in the speciﬁc test sample.olecular response for each patient at different time points after SCT using RT-
s ﬁgure is available in color online at www.bbmt.org).
Table 2
Results of Replicate RT-QPCR
Patient No. Baseline Follow-Up
Time from
SCT, mo
BCR- ABL/
ABL* (IS)
Total ABL
Transcripts
Level of MR Time from
SCT, mo
BCR- ABL/
ABL* (IS)
Total ABL
Transcripts
Level of MR
1 49 0 575035 MR5.5 71 0 597913 MR5.5
2 35 .0000862y 705622 MR5.5 55 0 646660 MR5.5
3 38 .0007393z 563238 47 0 1387143 MR6.5
4 110 0 997523 MR6 131 0 1263341 MR6.5
5 123 0 555769 MR5.5 145 0 690461 MR5.5
6 58 0 700630 MR5.5 NA
7 139 0 874248 MR5.5 161 0 950068 MR5.5
8 109 .0000484y 1067353 MR6.5 132 0 514529 MR5.5
9 122 0 938046 MR5.5 NA
10 68 0 1467748 MR6.5 89 0 505766 MR5.5
11 104 0 776272 MR5.5 125 0 271026 MR5
12 29 0 860351 MR5.5 51 0 532937 MR5.5
IS indicates international scale; NA, not available.
* Mean result of positive wells normalized to the international scale.
y PCR positive in 1 and 2 wells of 82 tested, below the background cut-off.
z PCR positive in 6 wells of 82 tested.
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Twelve CML patients were included in the study. In-
dications for SCT included advanced phase (accelerated
phase -2, blast crisis -3) and TKI intolerance in chronic phase
in 5 and 3 patients, respectively. Four patients underwent
SCT as ﬁrst-line therapy in the pre-imatinib era. Additional
characteristics of the study patients are shown in Table 1.
Results of regular RT-qPCR before inclusion in the study are
given in Figure 1.
rRT-qPCR Results
At the ﬁrst time point analysis, patients were at a median
of 68 (range, 29 to 123) months after transplantation; 110
and 38 months for patients in chronic and advanced,
respectively. BCR-ABL transcripts were detected in 3 of 12
patients but were above the background and, therefore,
considered true positive in only 1 (Table 2). This test was in a
patient 38 months after a myeloablative SCT for second
chronic phase after a myeloid blast crisis. Interestingly, this
patient had the longest disease duration before SCT and was
not treated with a TKI until after the blast crisis had occurred
(12 years after CML diagnosis).
Follow-up samples were available in 10 patients, drawn at
a median of 22 months from baseline (median of 107months
after SCT). No BCR-ABL transcripts were detected in all
samples, including the previously positive patient, at this
time point.
Assay Sensitivity
By increasing RT-qPCR replicates number, the absolute
number of ABL copies detected in 21 of the 22 assays done
was above 320,000, supporting at least an MR5.5. Of those,
assay sensitivity has allowed for the conﬁrmation of MR6 and
MR6.5 in 4 and 1 of the PCR negative patients, respectively.
MR5 was conﬁrmed in the last PCR-negative patient.
DISCUSSION
Molecular monitoring in BCR-ABLepositive leukemia has
become the standard of care, with well-established associa-
tions between milestone response and long-term outcome,
in particular for chronic phase CML patients [15]. Treatment
with TKI is not curative according to traditional deﬁnitions;
therefore, most TKI-treated patients have detectable BCR-ABLtranscripts even after long-term therapy. Treatment cessa-
tion trials have shown increased RT-qPCR levels in the ma-
jority of those patients [1,2,16]. The graft-versus-leukemia
effect of Allo-SCT, in contrast, could result in true cure, and
no evidence of BCR-ABL transcripts should be found in long-
term post-SCT CML patients. Indeed, using a highly sensitive
RT-qPCR, all patients tested negative for BCR-ABL with a
sensitivity of 105.5 to 106.5 when tested at least 47 months
after SCT. Encouragingly, 5 of the 12 patients in the current
study underwent transplantation because of advanced phase
CML, suggesting that cure is feasible even in this poor
prognosis subgroup.
rRT-qPCR is a highly sensitive method that can be used to
determine BCR-ABL transcript levels, even when present at
extremely low levels. Using this method to follow Allo-SCT
patients could assist in determining post-SCT in-
terventions; however, further studies are needed to clarify
the exact clinical role of this method. Indeed, several highly
sensitive PCR methods to detect BCR-ABL were recently
described, including digital PCR for mRNA and patient-
speciﬁc genomic DNAebased PCR [12,17,18]. A prospective
trial using these different sensitive methods after Allo-SCT
could be informative in this regard. Furthermore, follow-up
with sensitive methods could also assist in clinical de-
cisions regarding the addition of TKI in the post-SCT period
as either consolidation/preemptive therapy or at early signs
of molecular relapse. Finally, rRT-qPCR negativity in the
SCT setting could probably be very near the deﬁnition of
molecular disease cure.ACKNOWLEDGMENTS
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